08037400111
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese
Betamethasone Valerate
25.00 - 50.00 INR/Kilograms
Product Details:
- Shelf Life 1-3 Years
- CAS No 2152-44-5
- Purity(%) 98%
- Physical Form Solid
- Supply Ability : 1000 Kilograms Per Day
- Click to view more
X
Price And Quantity
- 25 Kilograms
- 25.00 - 50.00 INR/Kilograms
Product Specifications
- 98%
- 1-3 Years
- Solid
- 2152-44-5
Trade Information
- Cash Advance (CA), Cash in Advance (CID)
- 1000 Kilograms Per Day
- 7 Days
- Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
- All India
Product Description
Betamethasone valerate powder is a medication effective in the treatment of skin conditions of the scalp, like psoriasis and seborrhea. Betamethasone reduces swelling (inflammation), itch, and redness. This drug is part of the corticosteroid class. As a medium-strength corticosteroid, this medicine is effective.
Properties:
- IUPAC Name: [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6
- CAS Number: 2152-44-5
- Molecular Formula: C27H37FO6
- Application: A potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties
- Synonyms: betamethasone pentanoate; Betamethasone Valerate; VALISONE (11-beta, 16-beta)-l)oxy); 17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione-9-fluoro-11-bet; 17-valerate; Betamethasonevalerateester; betnovateat; celestoderm; (11beta,16beta)-9-fluoro-11, 21-dihydroxy-16-methyl-3, 20-dioxopregna-1,4-dien-17-yl pentanoate;
Manufacturing process:
It provides a new process route for synthesising betamethasone and series of its derivatives. As the original material, 1, 4, 9, 16-tetraene-pregna-3, 20-diketone is modified by 9, 11 bits, 16, 17 bits, and 21 bits in order to obtain betamethasone and the series products derived from it, for instance betamethasone acetate and betamethasone sodium phosphate. The process is advantageous in that the invention uses existing intermediates as the original material; there is a simple route; the material is readily available; expensive accessories are not needed; yield and cost are drastically better than in the past methods of synthesizing betamethasone; in addition, the use of existing intermediates enables combined production of dexamethasone and betamethasone products, thus decreasing manufacturing costs and industrial production conditions.
How to use:
A thin, even layer of betamethasone topical should be applied to the affected area of skin, then gently massaged in. You can apply the foam to your scalp by parting your hair, putting a tiny amount on the affected area, and gently rubbing it in
Dosage of usage:
Usual Adult Dose for:
- Dermatitis
- Plaque Psoriasis
Usual Pediatric Dose for:
- Dermatitis
Side effects:
Initially, there may be stinging, burning, itching, irritation, dryness, or redness of the skin. During the course of adjusting to the medication, these effects will disappear. Please notify your doctor or pharmacist if any of these side effects persist or worsen.
Warnings and precautions while using this product
If you are allergic to betamethasone or any of its components (e.g., hydrocortisone, prednisone), or if you have any other allergies, tell your doctor or pharmacist before you start using it. Inactive ingredients in this product may result in allergic reactions or other problems. For more information, consult your pharmacist.
Enter Buying Requirement Details
Other Products in 'Active Pharmaceuticals Ingredients (API)' category
Contact Us
- 311, Atlantis Heights, Sarabhai Main Road, Vadiwadi, Vadodara - 390007, Gujarat, India
- Phone :08037400111
- Fax :91-265-2313035
-
Send Inquiry
Mr. Nilesh Bansilal Sheth (Partner)
Mobile :08037400111
: nilesh.sheth70
MR. Tushar V. Kavade (Partner) : tushar.kavade
Send Inquiry
|
SHREEJI PHARMA INTERNATIONAL
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
